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Activated microglial cells play an important role in immune and inflammatory 
responses in CNS and play a role in neurodegenerative diseases. We examined the 
effects of lipoic acid (LA) on inflammatory responses of BV-2 microglial cells activated 
by lipopolysaccharide (LPS), and explored the underlying mechanisms of action of LA. 
BV-2 cells treated with LPS showed an up-regulation of mRNA of the pro-inflammatory 
molecules, inducible nitric oxide synthase (iNOS). LA suppressed the expression of 
iNOS and furthermore, LPS-induced production of nitrite. Moreover, LA suppressed the 
nuclear translocation of RelA, a component of nuclear factor-kappa B (NF-κB) that 
contains transcriptional activator domain for LPS. The mechanisms of LA-mediated 
anti-inflammatory effects on microglia remain unknown, and we suggested an 
involvement of Akt/glycogen synthase kinase-3β (GSK-3β) phosphorylation. The 
results showed that inhibitor of phosphatidylinositol 3-kinase prevented LA-mediated 
suppression of LPS induction of RelA and expression of iNOS. Furthermore, these 
inflammatory actions were prevented by GSK-3β inhibitors. These data demonstrate a 
role for LA as a chemical modulator of inflammatory responses by microglia, and thus 











     Microglial cells are important players in immune and inflammatory responses in 
the CNS (Nam et al. 2010), and their activation is implicated in several chronic 
neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease 
(PD) and brain ischemia (Kang et al. 2004). Activated microglial cells promote neuronal 
injury via the production of pro-inflammatory molecules such as the cytokines, tumor 
necrosis factor (TNF) α and interleukin (IL)-1β, and other cytotoxic molecules, such as 
reactive oxygen species (ROS) (Dheen et al. 2007). The overexpression of 
pro-inflammatory cytokines has emerged as an important determinant of the 
cytotoxicity associated with inflammation in neurodegenerative diseases (Jin et al. 
2007). Furthermore, excessive production of nitric oxide (NO) in activated glia, 
resulting from the production of inducible nitric oxide synthase (iNOS), is thought to 
play a role in neurodegenerative pathology. Therefore, promoting counter regulatory 
mechanisms is essential to avoid inflammation-mediated injury in the CNS (McCarty 
2006), and would thus require therapeutic agents that possess anti-inflammatory actions, 
targeting over-activated microglia cells. 
     Lipoic acid (LA) was identified as a cofactor for mitochondrial α-ketoacid 
dehydrogenases in mammals (Smith et al. 2004). LA may easily cross the blood brain 
barrier because of its small molecular size (206 g/mol) and high water and lipid 
solubility (Goraca and Asłanowicz-Antkowiak 2009). A number of studies have 
reported on the beneficial effects of LA on various disorders, such as hypertension 
(Thirunavukkarasu et al. 2004) and diabetes mellitus (Kamenova 2006). Although the 
cellular and molecular mechanisms associated with the positive actions of LA are 
partially understood for these diseases, little is known about its mechanistic actions 
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underlying anti-inflammatory responses through GSK-3β, including its effect on 
activated microglia (Zhang et al. 2007). Therefore, the present study aimed to 
investigate the effect of LA on LPS-activated BV-2 murine microglia cell lines and the 
effect of LA injection in LPS-exposed mice by examining their cortices. The results 
reported herein may thus provide critical information on the use of LA as a therapeutic 
agent via its suppression of microglial activation. 
 
2. Materials and methods 
2.1. Chemicals 
     LA was purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in 
phosphate-buffered saline (PBS) containing 0.33% 5 M NaOH. LPS was obtained from 
Sigma-Aldrich (Escherichia coli 0111:B4, Sigma-Aldrich, Tokyo, Japan). The 
phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002 (LY), was purchased from 
Sigma-Aldrich. The glycogen synthase kinase-3β (GSK-3β) inhibitor, lithium chloride 
(LiCl), and GSK-3β inhibitor VII were purchased from Wako (Osaka, Japan) and 
Calbiochem (San Diego, CA, USA), respectively. 
2.2. Cell culture and treatment  
     The BV-2, murine cell line was purchased from Banca Biologica e Cell Factory 
(Genoa, Italy) and maintained in RPMI1640 (Wako, Osaka, Japan) and 10% fetal 
bovine serum (FBS, Gibco, Grand Island, USA). The cells were pretreated with the 
inhibitors for 10 min followed by LA. After a 30-min incubation of the inhibitors and 
LA, LPS was added. 
2.3. RNA isolation and RT-PCR 
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     Total RNA was isolated from BV-2 cells using Sepasol RNAI (Nacalai Tesque, 
Kyoto, Japan). cDNA fragments were obtained by RT-PCR. We used the RNA PCR kit 
(AMV) Version 3 (Takara, Kyoto, Japan) to obtain the PCR products following the 
specific primers for: iNOS (5’-ACGAGACGGATAGGCAGAGA-3’(forward) and 
5’-AGCTGGAAGCCACTGACACT-3’(reverse)), GAPDH 
(5’-ACCACAGTCCATGCCATCAC -3’(forward) and 
5’-TCCACCACCCTGTTGCTGTA -3’(reverse)). The PCR products underwent 
electrophoresis and were stained with ethidium bromide. The product bands were 
quantified using Scion Image software (Scion Corporation, Frederick, MD, USA) and 
were normalized against the corrected GAPDH mRNA data.  
2.4. Determination of nitrite levels by the Griess assay 
     Nitrite levels were determined using the Griess method, as previously described 
by our group (Koriyama et al. 2009a). Briefly, the medium from treated cells cultured in 
24-well plates was removed and placed into a 96-well plate (50 μl per well). The 
medium was mixed with Griess reagent (1% sulfanilamide solution and 0.1% 
N-[1-naphthyl]-ethylenediamine dihydrochloride) for 10 min. Absorbance was 
measured at 550 nm using a microplate reader (Model 680, Bio-Rad Laboratories, 
Hercules, CA, USA). Sodium nitrite was used to construct the standard curve. 
2.5. Subcellular fractionation of RelA protein 
     BV-2 cells were lysed with hypotonic buffer (10 mM HEPES-KOH [pH7.9], 10 
mM KCl, 1.5 mM MgCl2, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, and 
protease inhibitor cocktail [Sigma-Aldrich, Tokyo, Japan]) and centrifuged (10,000 ×g, 
15 min at 4°C). The supernatants comprised of the cytoplasmic fractions. The pellets 
were incubated (30 min on ice) with a nuclear lysis buffer (20 mM HEPES-KOH 
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[pH7.9], 400 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 5% glycerol, and 
protease inhibitor cocktail). The generated lysates were centrifuged (18,000 ×g, 15 min 
at 4°C) and the resulting supernatants comprised of the nuclear fractions to be analyzed.  
2.6. Western blot analysis 
     Cultured BV-2 cells or mouse cortical tissue were extracted, and sample aliquots 
(30 μg of protein) were subjected to polyacrylamide gel electrophoresis using a 12.5% 
gel, as previously described (Koriyama et al. 2013). The separated proteins were 
transferred to a nitrocellulose membrane and incubated with the primary antibodies (all 
at 1:500): anti-iNOS, anti-GSK-3β or Akt (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), and anti-phospho-(p)-GSK-3β (Ser9), anti-p-Akt (Ser473) or anti-RelA (Cell 
Signaling Technology, Tokyo, Japan). The secondary antibody was alkaline 
phosphatase-labeled anti-rabbit IgG (1:500, Sigma-Aldrich). The immunoreactive 
protein bands were detected using the BCIP/NBT Kit (KPL, Gaithersburg, MD, USA). 
β-actin (1:500) (Gene Tex, San Antonio, TX) and Histone H4 (1:500) (Cell Signaling 
Technology) were used as an internal standard and a standard for nuclear proteins, 
respectively. The protein bands were analyzed via densitometry using Scion Image 
Software. All experiments were repeated at least three times. 
2.7. Animals and surgery 
     All experiments on animals were performed in accordance with the guidelines for 
animal experiments of Kanazawa University. Male C57BL/6 mice (8–9 weeks old) were 
anesthetized by intraperitoneal injection of sodium pentobarbital (30–40 mg/kg body 
weight). Mice were assigned to 6 groups: (1) normal (vehicle), (2) 30 mg/kg LA only, 
(3) 60 mg/kg LA only, (4) LPS (5 mg/kg) only, (5) LPS+LA 30 mg/kg, or (6) LPS+LA 
60 mg/kg. Solutions of LA were prepared immediately before use by dissolving 10 
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mg/ml LA in 120 mM Tris buffer, adjusting the pH to 7.4 followed by filter sterilization 
of the solution. LA was administered intraperitoneally once per day for 3 days. For the 
LPS-treated groups, LPS (in saline) was injected (5 mg/kg, intraperitoneally) 3 h after 
the final administration of LA, and tissue collected after 3 days, as previously described 
(Qin et al. 2007; Corona et al. 2012).  
2.8. Tissue preparation and immunohistochemistry 
     Tissue fixation and cryosectioning were performed, as previously described 
(Koriyama et al. 2009b). Briefly, the brain was dissected and then fixed in 4% 
paraformaldehyde solution containing 0.1 M phosphate buffer (pH 7.4) followed by 
immersion in sucrose (at 4 °C) starting at a 5% concentration and gradually increasing 
to 30% over 2 h. The brain was then embedded in optimal cutting temperature 
compound (Tissue Tek; Miles, Eikhart, IN, USA) and cryosectioned (30-μm-thick 
sections). Coronal sections of cortex at bregma -1.5 to -2.0 mm were used for 
immunohistochemistry. The frozen sections were mounted onto silane-coated glass 
slides and air-dried. After washing and blocking with Blocking One (Nacalai Tesque), 
brain sections were incubated with primary antibodies: anti-Iba1 (1:100) (Wako) and 
anti-iNOS (1:500) (Transduction Laboratories, Lexington KY, USA) at 4 °C, overnight. 
The sections were then incubated with fluorescent secondary antibodies (1:1000, 
Invitrogen) at room temperature. 
 
2.9. Double-staining immunohistochemistry 
     To identify the cells which express iNOS protein, we used brain sections treated 
with LPS (5 mg/kg, 3 days). After identification of microglial cells by 
immunohistochemistry with using primary antibody, anti-Iba1 (1:100, WAKO) and 
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fluorescent antibody, anti-rabbit Alexa Fluor 488 (1:1000, Invitrogen), samples were 
combined with anti-iNOS immunohistochemistry. We used anti-iNOS (1:500, 
Transduction Laboratories, Kexington KY, USA) as a primary antibody, and 
biotin-conjugated anti-mouse IgG (Santa Cruz Biotechnology, CA, USA) as a 
secondary antibody. Then, sections were treated with DyLight 594-conjugated 
NeutrAvidin (Thermo Scientific, Waltham, MA, USA). 
 
2.10. Quantification of microglia in the mouse cortex 
     Stereological counts of Iba1-positive microglial cells were undertaken in 30 μm 
sections adjacent to those used for quantitative immunohistochemistry in the cortex 
from retrospenial granular cortex to the secondary sematosensory cortex at Bregma 
~-1.6 (Paxinos and Franklin, 2001) from images taken by optical light microscope (at 
×200 magnification). To define the microglial cells, we used a signal/noise (S/N) ratio 
for each cell in each tissue. Cell bodies (> 5 μm) with a higher immunoreactivity (S/N 
ratio >3) were considered as Iba-1 positive microglia. To quantify the densities of 
immunoreactivity, we used ImageJ software (National Institutes of Health, Bethesda, 
Maryland). The values of microglia were presented as a percentage of those of the 
vehicle control group, and represented the average of 3 sections per mouse and a total of 
5 mice per group. 
2.11. Statistics 
     All results are reported as the mean ± SEM of three to five experiments. 
Differences between groups were analyzed using ANOVA, followed by Dunnett’s 
multi-comparison test with (PASW) Software (SPSS Inc., Chicago, IL, USA). 





3.1. LA decreased the LPS-induced expression of iNOS and production of nitrite in 
BV-2 cells. 
     RT-PCR was done to investigate the expression of mRNA of iNOS in 
LPS-exposed BV-2 cells. LPS treatment for 8 h significantly increased mRNA of iNOS 
in a concentration-dependent manner (50, 100, 200 ng/ml LPS) (data not shown). We 
used 200 ng/ml LPS in culture system hereafter. At 4, 6 and 8 h of LPS treatment, 
mRNA expression of iNOS was induced (without changes in the levels of GAPDH) 
(Fig. 1A). When compared with the control, an up-regulation of mRNA of iNOS (Fig. 
1A) occurred at 4 h of LPS treatment. Furthermore, the mRNA levels of iNOS was 
dramatically increased (8.4-fold) at 8 h. A pre-treatment of LA (200 and 400 μM; 30 
min) followed by LPS (8 h) markedly, but not completely, inhibited the LPS-induced 
expression of iNOS (Fig. 1B) in a concentration-dependent manner. LA also suppressed 
LPS-induced mRNA synthesis of another inflammatory mediators, TNFα, IL-1β (data 
not shown). We next focused on measuring the level of iNOS at the protein level to 
confirm the results obtained with the previous analyses regarding mRNA. Western 
blotting for iNOS revealed that LA (400 μM) significantly inhibited the LPS-induced 
expression of this catalytic enzyme for nitric oxide (Fig. 1C). Therefore, we evaluated 
the amount of nitrite production in BV-2 cells at 8 h of LPS treatment with or without 
LA (200 μM or 400 μM). We found that LPS increased the production of nitrite while 
LA significantly suppressed it in a concentration-dependent manner (Fig.1D). 
3.2 LA transiently activated Akt and inactivated GSK-3β in BV-2 cells. 
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     We recently reported that LA activates the phosphorylation of Akt in retinal 
precursor cell line of RGC-5 (Koriyama et al. 2013). GSK-3β is one of the major 
substrates of Akt, and is involved in the promotion of inflammation (Green and Nolan 
2012). Therefore, we evaluated the effect of LA on the phosphorylation of both Akt and 
GSK-3β. Levels of p-Akt and p-GSK-3β rapidly increased and peaked at 30-60 min, 
and then declined at 90 min after LA treatment (Fig. 2A and 2B, respectively). Next, we 
compared the ratio of p-GSK-3β to total GSK-3β under various culture conditions (Fig. 
2B). LA (60 min) significantly increased the levels of p-GSK-3β/GSK-3β. LPS alone 
tended to increase the expression levels of GSK-3β. In the data of p-GSK-3β/GSK-3β 
ratio, LPS significantly activated GSK-3β. LA restored the levels of the ratio of 
p-GSK-3β/GSK-3β to vehicle control levels. 
3.3 LA inhibited LPS-induced nuclear translocation of RelA in BV-2 cells. 
     The gene expression of inflammatory mediators (e.g. cytokines and iNOS) can be 
modulated by NF-κB. The most abundant form of NF-κB is a heterodimer of p50 and 
RelA (p65) subunits, of which the RelA subunit contains the transcriptional activator 
domain. Therefore, we investigated the effect of LA on LPS-induced nuclear 
translocation of RelA. RelA proteins localized in nuclei were significantly higher 1-2 h 
after LPS treatment (Fig. 3A). A pre-treatment of LA significantly attenuated the 
LPS-mediated nuclear translocation of RelA in a concentration-dependent manner 
(200–400 μM, Fig. 3B). These results indicated that the inhibition of RelA nuclear 
translocation by LA may have been one of the mechanisms responsible for the 
suppression of LPS-stimulated production of the inflammatory mediators determined 
previously. Moreover, the PI3K inhibitor, (LY), prevented the LA-mediated inhibition of 
LPS-stimulated nuclear translocation of RelA (Fig. 3C). Similar effects were also 
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observed with the GSK-3β inhibitors, LiCl and GSK-3β inhibitor VII (Fig. 3E), 
although either LiCl or GSK-3β inhibitor VII alone did not change the levels of RelA 
compared with vehicle control (Fig. 3D). These results suggest that LA mimics as 
GSK-3β inhibitors against LPS-induced inflammatory actions of RelA.  
3.4 LA attenuated LPS-induced iNOS expression through Akt activation/GSK-3β 
inactivation signaling in BV-2 cells. 
     To determine the role of p-Akt and p-GSK-3β on LA-induced anti-inflammatory 
action, we used LY and LiCl or GSK-3β inhibitor VII, respectively. Pretreatment of LY 
prevented LA-mediated suppression of iNOS expression during LPS exposure (Fig. 4A). 
Similar results were also observed by inactivating GSK-3β by using LiCl or GSK-3β 
inhibitor VII (Fig. 4B). Neither LiCl nor GSK-3β inhibitor VII alone had an effect on 
iNOS levels (data not shown). These results suggested that the anti-inflammatory effects 
of LA in BV-2 cells acted via the activation of Akt and inactivation of GSK-3β.  
3.5 LA reduced microglial activation in an in vivo model of neuroinflammation in 
the mouse cortex. 
     To evaluate the anti-inflammatory effect of LA in vivo, we induced 
neuroinflammation using LPS (5 mg/kg), and evaluated the effects of LA, administered 
3 days before the LPS treatment. Iba1 antibody was used to detect activated microglial 
cells (Qin et al. 2007). Light microscopy indicated that LPS treatment increased the 
number of Iba1-positive cells in the cortex (Fig. 5B) compared with the vehicle 
treatment group (Fig. 5A), which suggests microglial activation. A decrease in 
Iba1-positive cells was seen with 30 mg/kg and 60 mg/kg LA (Fig. 5C and 5D, 
respectively), which suggests a decrease in the number of activated microglia. When 
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quantified, pretreatment of mice with 30 and 60 mg/kg LA significantly reduced 
microglial activation in the cortex by 42.9 and 61.9%, respectively (Fig. 5E). 
3.6 LA suppressed the expression of iNOS in LPS-induced inflammation in the 
mouse cortex. 
     Our final objective was to evaluate the effect of LA on the presence of iNOS 
during LPS exposure in vivo. Fig 6A reveals that the majority of cells expressing iNOS 
by LPS treatment were also positively stained for anti-Iba1, indicating that these 
Iba1-positive cells were indeed activated. Light microscopy indicated that LPS 
treatment increased the number of iNOS-positive cells in the cortex (Fig. 6D) compared 
with the vehicle treatment group (Fig. 6B), and LA reduced this number (Fig. 6E). No 
change was seen with lipoic acid alone for 3 days (Fig. 6C). Western blotting and 
quantification of cortical iNOS confirmed these results. The expression of iNOS was 
significantly reduced by LA treatment during LPS exposure (Fig. 6F). LA alone did not 
change the levels of iNOS compared to vehicle control. 
 
4. Discussion 
     This study has revealed several interesting findings. First, we found that LA 
attenuated LPS-stimulated expression of the inflammatory mediator of iNOS, and 
another mediators, such as TNFα and IL-1β (data not shown) in BV-2 cells. In this 
model of inflammation, LA activated Akt and inactivated GSK-3β. Furthermore, LA 
inhibited LPS-stimulated RelA nuclear translocation via a dependent pathway that 
inactivated PI3K and GSK-3β. Finally, we found that LA prevented LPS-induced 
microglial activation and iNOS expression in the mouse cortex. 
4.1 Anti-inflammatory effect of LA in LPS-stimulated BV-2 cells. 
14 
 
Inflammation is closely associated with neurodegenerative diseases, such as AD 
(McGeer and McGeer 2003), PD (Barcia et al. 2003), post traumatic brain injury and 
brain ischemia (Rock and Peterson 2006). Prolonged activation of microglia by LPS 
may be directly toxic to neuronal cells because of the significant release of various 
inflammatory mediators, such as ROS and NO (Banati et al. 1993). Moreover, the 
release of NO and pro-inflammatory cytokines (e.g. TNFα and IL-1β) from activated 
microglia may be important factors for neuroinflammatory-mediated involvement in 
neurodegenerative diseases. Evidence to support this hypothesis has revealed that high 
levels of NO generated by iNOS are regarded to be key for inflammation and 
neurotoxicity after its conversion to peroxynitrite (via the superoxide anion). The 
expression of pro-inflammatory cytokines (TNFα and IL-1β) and iNOS in BV-2 cells is 
regulated by NF-κB (Jin et al. 2006). Additionally, up-regulation of LPS-stimulated 
iNOS-mediated production of NO and increased levels of TNFα and IL-1β are 
attenuated by the inhibition of NF-κB (Xie et al. 1994). Therefore, in the present study, 
we investigated the expression of pro-inflammatory genes and NF-κB signaling 
pathways to clarify the mechanism of action of LA in LPS-induced inflammation by 
activated glia. As expected, LA significantly inhibited LPS-induced production of 
inflammatory mediators in BV-2 cells. Furthermore, LA blocked the nuclear 
translocation of the RelA subunit. 
     Elevated levels of oxidative stress play an important role in chronic inflammation. 
As a result, LA has been studied for its antioxidant properties, occurring via the 
inhibition of NF-κB in cytokine-induced inflammation (Shay et al. 2009). Lee et al. 
reported that activation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) signaling 
followed by induced expression of antioxidative enzymes, such as heme oxygenase-1 
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(HO-1), showed anti-inflammatory activity (Lee and Chau 2002). We recently reported 
that LA stimulated Nrf2 signaling and promoted the expression of HO-1 in RGC-5 cells 
(Koriyama et al. 2013). In our data, LY partially cancelled the LA-induced 
anti-inflammatory activity (Fig. 3B and 4A). Therefore, the proposed link of the 
anti-inflammatory action of LA occurring via the antioxidative pathway may be 
involved. As a result, the mechanism by which LA induced an anti-inflammatory action 
may have been upstream of LPS-mediated nuclear translocation of RelA. 
4.2 The anti-inflammatory activity of LA involves Akt activation/GSK-3β 
inactivation in BV-2 cells. 
     We clearly showed that LA phosphorylated both Akt and GSK-3β in BV-2 cells. 
Inflammatory cytokine production is promoted by GSK-3β (Martin et al. 2005, Beurel 
and Jope 2009). GSK-3β is a highly conserved Ser/Thr protein kinase that is 
constitutively active (Cohen and Frame 2001; Jope and Jhonson 2004). Akt is a key 
mediator for the phosphorylation of the PI3K pathway. Activation of Akt 
phosphorylates (Ser473) several downstream targets of the PI3K pathway, including 
GSK-3β (Ser9). Phosphorylation of this target results in its inhibition (Cross et al. 1995). 
GSK-3β can both positively and negatively affect a variety of transcription factors that 
are critical in regulating the production of pro- and anti-inflammatory cytokines 
(Hoeflich et al. 2000; Grimes and Jope 2001; Németh et al. 2002). Our present results 
demonstrate that inhibition of GSK-3β in LPS-exposed BV-2 cells prevents the 
up-regulation of NF-κB nuclear translocation and subsequent expression of iNOS. 
Therefore, these findings strongly suggest that LA-mediated inactivation of GSK-3β (i.e. 
via Ser9 phosphorylation) plays a role in the anti-inflammatory response. Further 
evidence for such a role is shown by Huang et al. (2009) with their identification of 
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GSK-3β activation in the BV-2 cells in response to LPS stimulation. Furthermore, they 
demonstrate that GSK-3β inhibition blocks the production of NO and iNOS in 
LPS-exposed microglia.  
     NF-κB activity is precisely regulated by its interaction with the inhibitor of kappa 
B (IκB) (Baldwin 1996). NF-κB stimulates the phosphorylation of IκB by IκB kinase 
(IKK) and ubiquitin-dependent proteolysis of IκB, releasing NF-κB for nuclear 
translocation and subsequent transcriptional activation of NF-κB-regulated genes. 
Genetic depletion of GSK-3β suppresses inflammation-induced activation of IKK, and 
IκB phosphorylation and ubiquitination (Takada et al. 2004). In addition, LiCl-induced 
inhibition of GSK-3β results in decreased NF-κB activity (Grimes and Jope 2001). 
These reports confirm our hypothesis of an anti-inflammatory action of LA, via the 
inactivation-dependent effect on GSK-3β during LPS exposure to BV-2 cells. Several 
studies have reported that LA phosphorylates Akt in various cellular models (Zhang et 
al. 2007; Wang et al. 2011; Yamada et al. 2011; Deslauriers et al., 2012, Koriyama et al. 
2013). However, the mechanism of the anti-inflammatory action of LA via Akt and/or 
GSK-3β in BV-2 cells had not been clarified. In the current study, we used iNOS as a 
representative inflammatory mediator, and furthermore showed that its production was 
inhibited by LA-mediated down-regulation of nuclear translocation of RelA during LPS 
exposure to BV-2 cells. Additionally, this effect by LA was reversed using PI3K 
inhibitor or mimicked with either LiCl or GSK-3β inhibitor VII. Surprisingly however, 
LPS alone increased the levels of GSK-3β, a result also found by Green et al. (2012). 
The regulation of transcriptional activation of GSK-3β may be via genomic and 
non-genomic mechanisms (Rubio-Patiño et al. 2012). Our findings showed that LA 
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reversed LPS-activation of GSK-3β and promoted anti-inflammatory action. One of the 
mechanisms of this effect was found to be via Akt activation and GSK-3β inactivation.  
4.3 Possibility of LA as an anti-inflammatory agent 
     Increased levels of inflammatory mediators, particularly cytokines and activated 
microglia have been reported in many neurodegenerative diseases (Beurel 2011). In 
addition, GSK-3β is involved in the pathology of neurodegenerative diseases. Therefore, 
interventions using LA as an inhibitor of GSK-3β may be beneficial, by reducing the 
potential detrimental effects of inflammation concomitantly occurring with 
neurodegenerative processes. Aging-related neurological diseases are associated with a 
wide range of pathophysiological changes eventually leading to compromised cognitive 
status (Farkas and Luiten 2001). Interestingly, endogenous levels of LA have been 
found to be diminished during aging (Palaniappan and Dai 2007) and thus, may play a 
role in cognitive decline. 
     Overall, our study provides new insights into the effects of LA during 
LPS-induced inflammation, in which its mechanism of anti-inflammatory action occurs 
via Akt activation and GSK-3β inactivation in BV-2 cells.  
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Fig. 1 LA decreases LPS-induced expression of iNOS and nitrite production in 
BV-2 cells.  (A) Cells were treated for 8 h with 200 ng/ml of LPS, followed by 
RT-PCR analysis. LPS treatment at differing exposure times increased the mRNA of 
iNOS. (B) BV-2 cells were pretreated (30 min) with LA (200 μM or 400 μM) followed 
by LPS (200 ng/ml) for 8 h, and RT-PCR analysis was performed thereafter for iNOS. 
(C) Western blotting for iNOS and subsequent quantification. (D) Measurement of 
nitrite production by the Griess assay. *p < 0.05 vs vehicle control, **P < 0.01 vs 
vehicle control, +p < 0.01 vs LPS alone, ap < 0.01 vs LA (200 μM), bp < 0.01 vs LA 
(400 μM) (n=3).  
 
Fig. 2 LA activates Akt and inactivates GSK-3β in LPS-exposed BV-2 cells. (A) 
Time course of p-Akt and p-GSK-3β after LA treatment. Cells were treated with 400 
μM LA for various times until 90 min. Levels of activated Akt and inactivated GSK-3β 
rapidly increased at 30 min, peaked at 30–60 min and then declined at 90 min after LA 
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treatment. (B) LA reversed LPS-mediated activation of GSK-3β. Cells were pretreated 
with LA for 30 min and treated with or without LPS (30 min). *p < 0.01 vs vehicle 
control, +p < 0.01 vs LPS alone, #P< 0.01 vs LA alone (n=3). 
 
Fig. 3 Suppressive effect of LA on nuclear translocation of RelA induced by LPS 
occurs via PI3K- and GSK-3β- dependent mechanisms in BV-2 cells. (A) Time 
course of RelA nuclear translocation by LPS (200 ng/ml). *p < 0.05 vs vehicle control, 
**p < 0.01 vs vehicle control. (B) Nuclear translocation of RelA protein in BV-2 cells 
after LPS (200 ng/ml) treatment with or without the LA pre-treatment (30 min). * p < 
0.05 vs vehicle control, **p < 0.01 vs vehicle control, +p < 0.01 vs LPS alone (n=3). (C) 
PI3K inhibitor prevented the inhibition of LPS-induced RelA nuclear translocation by 
LA. BV-2 cells were pretreated (30 min) with LA (400 μM) or LY (10 μM, 40 min) 
followed by LPS (2 h), and levels of translocated RelA were measured. * p < 0.01 vs 
vehicle control, +p < 0.01 vs LPS alone, # p < 0.01 vs LPS plus LA, ap < 0.01 vs LA 
(400 μM) (n=3). (D) GSK-3β inhibitors had no effect on RelA levels of vehicle control. 
(E) GSK-3β inhibitors prevented LPS-induced nuclear translocation of RelA. Cells were 
pretreated (30 min) with LiCl (10 mM) or GSK-3β inhibitor VII (1 μM) followed by 
LPS (2 h). Levels of nuclei-containing RelA were then measured. *p < 0.01 vs vehicle 
control, +p < 0.01 vs LPS alone (n=3).  
 
Fig. 4 LA prevents LPS-induced expression of iNOS via PI3K and by inhibitors of 
GSK-3β in BV-2 cells. (A) PI3K inhibitor prevented the inhibition of LPS-induced 
iNOS expression by LA in BV-2 cells. BV-2 cells were pretreated (30 min) with LA 
(400 μM) with or without LY (10 μM, 40 min) followed by LPS treatment (8 h). 
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Western blot analysis was then performed. *p < 0.05 vs vehicle control, **p < 0.01 vs 
vehicle control, +p < 0.01 vs LPS alone, #p < 0.01 vs LPS plus LA (n=3). (B) GSK-3β 
inhibitors reversed LPS-induced expression of iNOS in BV-2 cells. Cells were 
pretreated (30 min) with LiCl (10 mM) or GSK-3β inhibitor VII (1 μM) for 30 min 
followed by LPS incubation (8 h). Western blot analysis was then performed. *p < 0.05 
vs vehicle control, **p < 0.01 vs vehicle control, +p <0.05 vs LPS alone, ++p < 0.01 vs 
LPS plus LA (n=3). 
 
Fig. 5 Effect of LA on microglial activation in a mouse model of LPS-induced 
neuroinflammation. LA was administered intraperitoneally once per day for 3 days 
before LPS treatment (5 mg/kg, 3 days). Representative photomicrographs of microglial 
activation in the cortex of each group: (A) Vehicle control, (B) 5 mg/kg LPS, (C) LPS 
plus LA (30 mg/kg), (D) LPS (5 mg/kg) plus LA (60 mg/kg). (E) Quantification of 
microglial activation was performed by counting the number of Iba1-immunoreactive 
cells in the cortex. Data were presented as a percentage of the vehicle control group 
value. *p < 0.01 vs vehicle control, +p < 0.05 vs LPS alone, ap < 0.01 vs LA (30 mg/kg), 
bp < 0.01 vs LA (60 mg/kg) (n=3).  (n=12). Scale= 50 μm. 
 
Fig. 6 LA inhibits LPS-induced iNOS expression in mouse cortex. (A) LPS-induced 
iNOS expression in Iba1-positive microglia in the cortex. The localization of iNOS 
expression in cortex was confirmed using the microglial marker, Iba1. LA was 
administered intraperitoneally once per day for 3 days before LPS treatment (5 mg/kg, 3 
days). Representative photomicrographs iNOS expression in the cortex of each group: 
(B) Vehicle control, (C) LA (60 mg/kg), (D) LPS (5 mg/kg), (E) LPS plus LA (60 
26 
 
mg/kg). (F) Quantification of iNOS expression was performed by western blot of 
cortical tissue. *p < 0.05 vs vehicle control, **p < 0.01 vs vehicle control, +p < 0.05 vs 
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